| Overview |
| bs-9428R-Cy7 |
| Tal1 Polyclonal Antibody, Cy7 Conjugated |
| IF |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Tal1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| bHLHa17; Class A basic helix-loop-helix protein 17; SCL antibody; Stem cell protein; T cell acute lymphocytic leukemia 1; T cell acute lymphocytic leukemia 1 protein; T cell leukemia/lymphoma 5 protein; T-cell acute lymphocytic leukemia protein 1; T-cell leukemia/lymphoma protein 5; Tal 1; Tal 1 product; TAL 1 protein; TAL-1; tal1; TAL1_HUMAN; TCL 5; TCL5. |
| Activation of TAL1 characterizes up to 60% of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors. |
| Application Dilution |
| IF |
WB1:300-5000 |
Powered by Bioz